推荐产品
等级
pharmaceutical primary standard
API类
levetiracetam
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
CC[C@H](N1CCCC1=O)C(N)=O
InChI
1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
InChI key
HPHUVLMMVZITSG-LURJTMIESA-N
基因信息
human ... CACNA1B(774) , SV2A(9900)
正在寻找类似产品? 访问 产品对比指南
1 of 4
此商品 | 21878 | 21877 | 21884 |
|---|---|---|---|
| fluorescence λex 492 nm; λem 517 nm in 0.1 M Tris pH 8.0 (esterase) | fluorescence λex 492 nm; λem 517 nm in DMF | fluorescence λex 492 nm; λem 517 nm in 0.1 M Tris pH 8.0 | fluorescence λex 470 nm; λem 529 nm in 0.1 M Tris pH 8.0 (esterase) |
| solubility DMF: soluble, DMSO: soluble | solubility DMF: soluble, DMSO: soluble | solubility - | solubility DMF: soluble, DMSO: soluble, methanol: soluble |
| form solid | form powder | form powder | form - |
| storage temp. −20°C | storage temp. −20°C | storage temp. - | storage temp. −20°C |
| Quality Level 200 | Quality Level 200 | Quality Level 200 | Quality Level 100 |
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Levetiracetam EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
左乙拉西坦是一种具有抗癫痫活性的吡咯烷。
左乙拉西坦是一种具有抗癫痫活性的吡咯烷。左乙拉西坦的立体选择性结合仅限于中枢神经系统的突触质膜，而在周围组织中不发生立体选择性结合。左乙拉西坦在不影响正常神经元兴奋性的情况下抑制簇状放电，这表明它可以选择性地阻止癫痫样簇状放电的超同步和发作活动的传播。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Radica M Stepanović-Petrović et al.
Anesthesia and analgesia, 115(6), 1457-1466 (2012-11-13)
We have recently shown that levetiracetam, administered systemically, exerts an antihyperalgesic effect in a rat inflammatory pain model. In this study, we examined whether levetiracetam has local peripheral antihyperalgesic/anti-edematous effects in the same model of localized inflammation and whether opioidergic
D Consoli et al.
Cerebrovascular diseases (Basel, Switzerland), 34(4), 282-289 (2012-11-07)
Strokes are the leading cause of epileptic seizures in adults and account for 50% of seizures in those over the age of 65 years. The use of antiepileptic drugs to prevent recurrent poststroke seizures is recommended. One hundred and twenty-eight
Hai-Dun Yan et al.
Brain research bulletin, 90, 142-148 (2012-10-31)
Levetiracetam (LEV) is a widely used antiepileptic agent for partial refractory epilepsy in humans. LEV has unique antiepileptic effects in that it does not inhibit electroshock- or pentylenetetrazol-induced convulsion, but does inhibit seizures in kindling animal and spontaneously epileptic rat
Marjolein de Groot et al.
Neuro-oncology, 15(2), 216-223 (2012-12-13)
Treatment of high-grade glioma (HGG) patients with anti-epileptic drugs (AEDs) has met with various side effects, such as cognitive deterioration. The cognitive effects of both older and newer AEDs in HGG patients are largely unknown. The aim of this study
Katherine A Lyseng-Williamson
Drugs, 71(4), 489-514 (2011-03-15)
Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial onset seizures with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持
